Search -

Displaying 501 - 520 of 711

Sort: Relevancy | Date

News Daily News

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

Michael O'Riordan

April 11, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Daily News

‘Constellation of Cardiovascular Stressors’ Puts Firefighters at Risk for MI

L.A. McKeown

April 03, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

News Conference News ACC 2017

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

Todd Neale

March 18, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

Michael O'Riordan

March 15, 2017

News Daily News

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

Michael O'Riordan

March 13, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Conference News ACC 2017

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Michael O'Riordan

March 10, 2017

News Conference News ACC 2017

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

L.A. McKeown

March 09, 2017

News Daily News

No IV Hydration for Contrast Nephropathy? AMACING Trial Challenges a Cornerstone of Prophylaxis

Shelley Wood

March 06, 2017

News Daily News

Mixed Clinical, Biomarker Score Might Boost CAD Risk Prediction

Yael L. Maxwell

March 03, 2017

News Daily News

Ship Out, Shape Up? Post-ACS Patients Not Getting Enough Physical Activity

Yael L. Maxwell

March 01, 2017

News Daily News

Coronary Calcium IDs Higher Heart Disease Risk Even in Younger Adults

Todd Neale

February 10, 2017

News Daily News

10-Year Follow-up of Early DES Shows Steady Risk of Late Events

L.A. McKeown

February 08, 2017

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

News Daily News

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Michael O'Riordan

January 18, 2017

News Daily News

HIV-Positive Patients Face Elevated Rate of Type 2 MI

Caitlin E. Cox

January 12, 2017

Advertisement

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

‘Constellation of Cardiovascular Stressors’ Puts Firefighters at Risk for MI

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

No IV Hydration for Contrast Nephropathy? AMACING Trial Challenges a Cornerstone of Prophylaxis

Mixed Clinical, Biomarker Score Might Boost CAD Risk Prediction

Ship Out, Shape Up? Post-ACS Patients Not Getting Enough Physical Activity

Coronary Calcium IDs Higher Heart Disease Risk Even in Younger Adults

10-Year Follow-up of Early DES Shows Steady Risk of Late Events

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

HIV-Positive Patients Face Elevated Rate of Type 2 MI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content